doi:10.3969/j.issn.1673-8640.2023.12.008

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 13

[1]	BECK L H Jr, BONEGIO R G, LAMBEAU G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21. DOI URL
[2]	HOFSTRA J M, BECK L H J R, BECK D M, et al. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2011, 6(6):1286-1291. DOI URL
[3]	刘莎莎, 张丽, 李素华, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病诊断中意义[J]. 中华实用诊断与治疗杂志, 2016, 30(4):405-406.
[4]	FLOEGE J, BARBOUR S J, CATTRAN D C, et al. Management and treatment of glomerular diseases(part 1) :conclusions from a kidney disease:improving global outcomes(KDIGO) controversies conference[J]. Kidney Int, 2019, 95(2):268-280. DOI URL
[5]	YY/T 1789.2-2021. 体外诊断检验系统性能评价方法第2部分:正确度[S].
[6]	YY/T 1789.3-2022. 体外诊断检验系统性能评价方法第3部分:检出限与定量限[S].
[7]	COUSER W G. Primary membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12(6):983-997. DOI URL
[8]	伍敏, 魏青, 刘必成. 原发性膜性肾病诊断及治疗新进展[J]. 中国实用内科杂志, 2023, 43(3):183-187.
[9]	VAN DE LOGT A E, FRESQUET M, WETZELS J F, et al. The anti-PLA2R antibody in membranous nephropathy:what we know and what remains a decade after its discovery[J]. Kidney Int, 2019, 96(6):1292-1302. DOI URL
[10]	CATTRAN D C, BRENCHLEY P E. Membranous nephropathy:integrating basic science into improved clinical management[J]. Kidney Int, 2017, 91(3):566-574. DOI URL
[11]	DE VRIESE A S, GLASSOCK R J, NATH K A, et al. A proposal for a serology-based approach to membranous nephropathy[J]. J Am Soc Nephrol, 2017, 28(2):421-430. DOI PMID
[12]	FRANCIS J M, BECK L H J R, SALANT D J. Membranous nephropathy:a journey from bench to bedside[J]. Am J Kidney Dis, 2016, 68(1):138-147. DOI URL
[13]	胡广. 血清抗PLA2R抗体在特发性膜性肾病诊断及病情评估中应用的可行性分析[D]. 南宁: 广西中医药大学, 2020.

样本	批内精密度					批间精密度
	CLIA			ELISA			CLIA			ELISA
		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %	$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %
低值	16.34	0.20	1.23	12.33	1.01	8.18	16.04	0.42	2.59	13.65	1.18	8.67
高值	1 082.32	15.69	1.45	1 053.55	89.66	8.51	1 077.98	22.85	2.12	1 056.20	94.11	8.91

样本	批内精密度					批间精密度
	CLIA			ELISA			CLIA			ELISA
		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %		$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %	$\bar{x}$/ （RU/mL）	s/（RU/mL）	CV/ %
低值	16.34	0.20	1.23	12.33	1.01	8.18	16.04	0.42	2.59	13.65	1.18	8.67
高值	1 082.32	15.69	1.45	1 053.55	89.66	8.51	1 077.98	22.85	2.12	1 056.20	94.11	8.91

ELISA	CLIA		合计
ELISA	阳性	阴性	合计
阳性	112	1	113
阴性	9	165	174
合计	121	166	287

ELISA	CLIA		合计
ELISA	阳性	阴性	合计
阳性	112	1	113
阴性	9	165	174
合计	121	166	287

组别	例数	CLIA/（RU/mL）	ELISA/（RU/mL）
PMN组	135	225.50±194.79	196.12±160.67
非PMN组	152	2.47±1.81	4.12±2.52
t值		6.06	2.46
P值		<0.01	<0.01

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 13

Related Articles 15

Recommended Articles

Metrics

[1]	DUAN Pengcang, DONG Ruifang, LIU Xiaoman, CAO Yang, WANG Ruoxi. Correlation between serum Trx2，P-tau and total magnetic resonance imaging load score and cognitive function in patients with cerebral small vessel disease [J]. Laboratory Medicine, 2024, 39(1): 1-6.
[2]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[3]	ZHANG Yang, ZHANG Dehe, TANG Shiyue, ZHANG Jun, WANG Jianming, CHEN Ling. Predictive value of soluble CD163 combined with Charlson index for esophageal variceal bleeding in patients with liver cirrhosis [J]. Laboratory Medicine, 2024, 39(1): 19-25.
[4]	LIU Bohan, LIU Yiwen, HE Yiqing, LU Renquan, DU Yan, ZHANG Guoliang, GUO Qian, GAO Feng, YANG Cuixia. Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer [J]. Laboratory Medicine, 2024, 39(1): 26-30.
[5]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[6]	ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying. Synergistic diagnosis of THR mRNA and ALCAT1 in hyperthyroidism heart disease [J]. Laboratory Medicine, 2024, 39(1): 60-67.
[7]	. [J]. Laboratory Medicine, 2024, 39(1): 68-70.
[8]	LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12.
[9]	JIANG Haoqin, XU Qianqian, XU Liming, GUAN Ming. Homogenization management and practice of clinical blood and body fluid determinations [J]. Laboratory Medicine, 2024, 39(1): 95-99.
[10]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[11]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[12]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[13]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[14]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[15]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.